Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA4 | P22748 | 3/20 | 0.54 |
| ▸ | CA6 | P23280 | 3/20 | 0.54 |
| ▸ | CA5A | P35218 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.54 |
| ▸ | F13A1 | P00488 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | THPO | P40225 | 2/20 | 0.54 |
| ▸ | CASP2 | P42575 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020603 | 0.89 | SLC6A5 (0.54) | CASP2PAOX | |
| SCHEMBL1886044 | 0.89 | — | — | |
| Octadecylamine SCHEMBL27470135 | 0.88 | SLC6A5 (0.56) | CASP2PAOX | |
| Decylamine SCHEMBL27634409 | 0.88 | SLC6A5 (0.56) | CASP2PAOX | |
| SCHEMBL9512084 | 0.87 | CA3 (0.47) | CA12CA2CA4CA6CA5A | |
| SCHEMBL8351641 | 0.87 | PAOX (0.58) | CA12CA2CA4CA6CA5A | |
| SCHEMBL12085489 | 0.86 | PAOX (0.53) | CA12CA2CA4CA6CA5A | |
| SCHEMBL14360491 | 0.86 | PAOX (0.53) | CA12CA2CA4CA6CA5A | |
| SCHEMBL19186288 | 0.85 | PAOX (0.61) | CASP2MEN1KMT2APAOXLMNA | |
| SCHEMBL10276927 | 0.85 | PAOX (0.61) | CASP2MEN1KMT2APAOXLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090417-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO. (US) | 2025-05-01 | — | — | WO | claimed |
| WO-2025090422-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO. (US) | 2025-05-01 | — | — | WO | claimed |
| EP-0782862-B1 | GENETIC MATERIAL CONTAINING COMPOSITION | DAIICHI SEIYAKU CO (JP) | 2004-10-27 | — | — | EP | claimed |
| EP-0782862-A1 | GENETIC MATERIAL CONTAINING COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-07-09 | — | — | EP | claimed |
| US-20260035673-A1 | COMPOSITION FOR CRYOPRESERVATION, CRYOPRESERVATION METHOD, AND FROZEN CELL OR BIOLOGICAL TISSUE | SANYO-ONODA CITY PUBLIC UNIVERSITY CORPORATION (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12428634-B2 | Methods for extracting bioactive small RNAS from plants and mushrooms | MIRNAGREEN S.R.L. (IT) | 2025-09-30 | — | — | US | disclosed |
| EP-4563695-A1 | COMPOSITION FOR CRYOPRESERVATION, CRYOPRESERVATION METHOD, AND FROZEN CELL OR BIOLOGICAL TISSUE | Sanyo-Onoda City Public University Corporation (JP) | 2025-06-04 | — | — | EP | disclosed |
| CN-119300869-A | Composition for weakening skin barrier function containing anionic long-chain lipid, and dispersion containing complex containing cationic long-chain lipid, anionic long-chain lipid and drug dispersed therein | 国立大学法人九州大学 | 2025-01-10 | — | — | CN | disclosed |
| CN-118846026-A | Broad-spectrum influenza virus vaccine | 摩登纳特斯有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240344054-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | MIRNAGREEN S.R.L. (IT) | 2024-10-17 | — | — | US | disclosed |
| EP-4384612-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | Mirnagreen S.r.l. (IT) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024024892-A1 | COMPOSITION FOR CRYOPRESERVATION, CRYOPRESERVATION METHOD, AND FROZEN CELL OR BIOLOGICAL TISSUE | 公立大学法人山陽小野田市立山口東京理科大学 | 2024-02-01 | — | — | WO | disclosed |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| EP-1867633-A1 | Polyamine analogues as therapeutic and diagnostic agents | MediQuest Therapeutics, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2005062767-A2 | HOXD3, HOXA3, AND HOXB3 COMPOSITIONS AND METHODS FOR IMPROVED WOUND HEALING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-0782862-B1 | GENETIC MATERIAL CONTAINING COMPOSITION | DAIICHI SEIYAKU CO (JP) | 2004-10-27 | — | — | EP | disclosed |
| WO-2001042200-A1 | CATIONIC AMPHIPHILES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035673-A1 | COMPOSITION FOR CRYOPRESERVATION, CRYOPRESERVATION METHOD, AND FROZEN CELL OR BIOLOGICAL TISSUE | MCL1, TNNC1, TNNI3 | CA12 1101/4885CA2 1603/4885CA4 1990/4885 |
| US-20120289604-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | CA12 2977/4885CA2 3322/4885CA4 4455/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | CA12 2977/4885CA2 3322/4885CA4 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.